Advertisement Peregrine compound enhances multiple chemo drugs - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Peregrine compound enhances multiple chemo drugs

A recently published report has shown that Peregrine Pharmaceuticals' NHS76/PEP2 enhances the efficacy of multiple chemotherapeutic agents, including Bristol-Myers Squibb's Taxol, by up to threefold.

Peregrine Pharmaceuticals today announced that a paper titled “NHS76/PEP2, a Fully Human Vasopermeability-Enhancing Agent to Increase the Uptake and Efficacy of Cancer Chemotherapy,”

The paper, which was published in the Clinical Cancer Research journal, shows that NHS76/PEP2 greatly enhanced the uptake and efficacy of a variety of chemotherapeutic agents in solid tumor models.

The publication contains data showing that pretreatment with NHS76/PEP2, Peregrine’s lead vasopermeability-enhancing agent (VEA), enhanced the efficacy of chemotherapy in tumors known to be sensitive to the specific drugs. In addition, the report shows that NHS76/PEP2 plus chemotherapy also generated responses in tumors normally resistant to specific therapies, such as MAD109 murine lung carcinoma treated with paclitaxel (Taxol), vinblastine (Eli Lilly’s Velban) or 5-FU.

Moreover, improvements in drug uptake were seen in as little as one to two hours following pretreatment with NHS76/PEP2.

NHS76/PEP2 is the result of a fusion protein between NHS76, a fully human version of one of Peregrine’s tumor necrosis therapy antibodies, and PEP2, a peptide derived from interleukin 2.